{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T00:55:59Z","timestamp":1784940959563,"version":"3.55.0"},"reference-count":39,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T00:00:00Z","timestamp":1679961600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Respiratory J"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The aim of this research is to investigate the feasibility of folate receptor\u2010positive circulating tumor cells (FR+CTCs) as a biomarker for the diagnosis of malignant pulmonary nodules and the correlation between clinicopathological factors and FR+CTC levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients initially diagnosed with one or more pulmonary nodules from a computed tomography scan were prospectively included. Three milliliters of peripheral blood was collected from each participant for FR+CTC analysis prior to surgery. Clinical and pathological parameters and FR+CTC levels were compared between patients with lung cancer and benign diseases.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Six hundred fifty\u2010three patients had lung cancer and the other 124 had benign lung diseases based on pathological examinations of the resected specimens. The median FR+CTC value of the lung cancer group was 12.0\u00a0(95% CI 9.6\u201316.2)\u00a0FU\/3\u00a0mL and that of the benign group was 7.2\u00a0(95% CI 5.78\u201311.2)\u00a0FU\/3\u00a0mL. The difference was statistically significant (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001). In a receiver operating characteristic analysis to distinguish the two groups, the area under curve of FR+CTC was 0.7457 (95% CI 0.6893\u20130.8021; <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.0001) using a cutoff of 8.65\u2009FU\/3\u00a0mL. The sensitivity was 86.37%, and the specificity was 74.19%. Combined with conventional serum tumor biomarkers, the area under curve was 0.922 (0.499\u20130.963). The sensitivity was 92.20%, and the specificity was 83.05%. FR+CTC levels were related to tumor staging (<jats:italic>P4<\/jats:italic>\u00a0&lt;\u20090.001), the degree of tumor invasion both in single (<jats:italic>P<\/jats:italic>\u2009=\u20090.011) and multiple lesions (<jats:italic>P<\/jats:italic>\u2009=\u20090.022), pathological subtypes (<jats:italic>P<\/jats:italic>\u2009=\u20090.013), and maximum tumor diameter (<jats:italic>P<\/jats:italic>\u2009=\u20090.014).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>FR+CTC is an effective and reliable biomarker for the diagnosis of lung cancer. Further, FR+CTC level is correlated with tumor staging, degree of invasion, pathological subtypes, and tumor size.<\/jats:p><\/jats:sec>","DOI":"10.1111\/crj.13601","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T22:53:51Z","timestamp":1680044031000},"page":"374-383","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The value of folate receptor\u2010positive circulating tumor cells in the diagnosis of lung cancer and its correlation with clinical characteristics"],"prefix":"10.1111","volume":"17","author":[{"given":"Yunjian","family":"Xu","sequence":"first","affiliation":[{"name":"Department of Clinical Lab The First Affiliated Hospital of Guangzhou Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianjun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Clinical Lab The First Affiliated Hospital of Guangzhou Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Clinical Lab The First Affiliated Hospital of Guangzhou Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongping","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Clinical Lab The First Affiliated Hospital of Guangzhou Medical University  Guangzhou China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,3,28]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.20073"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.3945\/an.116.012211"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432\u2010017\u20102522\u20103"},{"issue":"7","key":"e_1_2_10_5_1","first-page":"3099","article-title":"Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21\u20101 in non\u2010small cell lung cancer","volume":"30","author":"Tomita M","year":"2010","journal-title":"Anticancer Res"},{"issue":"5","key":"e_1_2_10_6_1","first-page":"1855","article-title":"Clinical relevance of thymidine kinase for the diagnosis, therapy monitoring and prognosis of non\u2010operable lung cancer","volume":"30","author":"Holdenrieder S","year":"2010","journal-title":"Anticancer Res"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arbres.2010.04.005"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346\u20108138.13657"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.11.025"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature20785"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.12.003"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2006.12.014"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13059\u2010014\u20100448\u20105"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.23717"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V93.11.3940"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ab.2004.12.026"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000606"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.7150\/jca.16856"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.17039"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1513\/pats.201107\u2010042ST"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0080458"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00103\u2010018\u20102834\u20108"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.22367"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.27309"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22168661"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc.2017.7"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2011.405"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e31824de09c"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_905_17"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S184532"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.21037\/jtd.2016.05.38"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759\u20107714.12851"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.3978\/j.issn.2305\u20105839.2015.11.18"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/smll.202001695"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1593\/tlo.13535"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2015\u20100431\u2010OA"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.519"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012\u20100176\u2010OA"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885\u2010020\u20106524\u20101"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2019.02.028"}],"container-title":["The Clinical Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/crj.13601","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T14:21:21Z","timestamp":1692454881000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/crj.13601"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,28]]},"references-count":39,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["10.1111\/crj.13601"],"URL":"https:\/\/doi.org\/10.1111\/crj.13601","archive":["Portico"],"relation":{},"ISSN":["1752-6981","1752-699X"],"issn-type":[{"value":"1752-6981","type":"print"},{"value":"1752-699X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,28]]},"assertion":[{"value":"2022-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-02-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-03-28","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}